BOCA RATON, Fla., Aug. 9, 2001 (PRIMEZONE) -- Disease Sciences (OTCBB:DISE) Thursday announced that its Chief Executive Officer Dr. Wayne Goldstein conducted an Internet interview which can be heard at www.equitybroadcast.com.
Dr. Goldstein discusses Disease Sciences's business model, several recent appointments to Disease Sciences' Scientific Advisory Board, as well as the recent divestiture of a subsidiary.
To hear the interview, please visit http://www.equitybroadcast.com.
To receive an investor kit and periodic updates on DISE directly from the company, sign up at http://investorcafe.net/DISE.htm.
About Disease Sciences: Disease Sciences, Inc. is a publicly traded developmental stage biopharmaceutical/clinical diagnostics Company planning to employ a broad array of technologies to detect, identify and quantify substances in blood or other bodily fluids and tissues. Disease Sciences intends to target and develop proprietary pharmaceutical compounds and new technologies, its primary goal will be a Transmissible Spongiform Encephalopthy (TSE) test, useful in the diagnosis of TSE diseases such as Scrapie in sheep, Bovine Spongiform Encephalopathy (BSE) in cattle (commonly known as "mad-cow disease"), Chronic Wasting Disease (CWD) in wild deer and elk and Creutzfeldt-Jakob Disease (CJD). Test results are to be used in the diagnosis, detection, evaluation, monitoring and potential treatment of diseases and other medical conditions.
Disease Sciences plans to: (1) identify, acquire and exploit rights to new technologies and compounds relating to BSE, CJD and other neurological disorders; (2) enhance the value of those assets through further research and clinical testing; (3) perform clinical studies towards regulatory approval and attempt to market its drugs through profitable licensing agreements with major pharmaceutical companies; (4) Work to develop other promising compounds in-house and in collaboration with third parties. Disease Sciences intends to develop corporate partnerships with established and well-capitalized pharmaceutical companies for the clinical development of its compounds and for their production, commercialization and marketing.
A number of statements contained in this press release are forward-looking statements which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development, and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions and the ability to secure additional sources of financing. The actual results that DISE may achieve could differ materially from any forward-looking statements due to such risks and uncertainties. EquityBroadcast (EquityThunder, Inc.) received from DISE a fee of $3,000 in exchange for interview production, interview broadcast, service, consulting and technology licensing fees for various online financial and shareholder communications services and technologies.